Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.52 |
| ▸ | RELA | Q04206 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30132805 | 1.00 | MAPT (0.52) | MAPTMAPK1RAB9ANPC1NFKB1 | |
| Butane SCHEMBL7723409 | 0.99 | MAPT (0.51) | MAPTMAPK1RAB9ANPC1NFKB1 | |
| SCHEMBL2107427 | 0.88 | MAPT (0.51) | MAPTMAPK1RAB9ANPC1NFKB1 | |
| SCHEMBL15709862 | 0.86 | LMNA (0.61) | MAPTMAPK1RAB9ANPC1NFKB1 | |
| SCHEMBL27856348 | 0.85 | MAPT (0.52) | MAPTMAPK1RAB9ANPC1NFKB1 | |
| Ethyl Acetate SCHEMBL29391722 | 0.84 | RAB9A (0.48) | MAPTMAPK1RAB9ANPC1NFKB1 | |
| SCHEMBL3796044 | 0.82 | MAPK1 (0.61) | MAPTMAPK1RAB9ANPC1ALDH1A1 | |
| SCHEMBL31031180 | 0.82 | MAPK1 (0.61) | MAPTMAPK1RAB9ANPC1ALDH1A1 | |
| SCHEMBL31213829 | 0.81 | ALDH1A1 (0.53) | MAPTMAPK1RAB9ANPC1NFKB1 | |
| SCHEMBL27985684 | 0.81 | ALDH1A1 (0.53) | MAPTMAPK1RAB9ANPC1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 76 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499629-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | Oncopia Therapeutics, Inc. D/B/A SK Life Science Labs (US) | 2025-02-05 | — | — | EP | disclosed |
| EP-4143182-B1 | NOVEL COMPOUNDS USEFUL AS POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS | RHIZEN PHARMACEUTICALS AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| US-20240327402-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| EP-4382511-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY | Abbisko Therapeutics Co., Ltd. (CN) | 2024-06-12 | — | — | EP | disclosed |
| US-20240109885-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | HEPTARES THERAPEUTICS LIMITED (GB) | 2023-12-05 | — | — | US | disclosed |
| EP-4257584-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| EP-4257584-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Abbisko Therapeutics Co., Ltd. (CN) | 2023-10-11 | — | — | EP | disclosed |
| WO-2023183919-A1 | BICYCLIC HETEROARYL-CONTAINING COMPOUNDS AS IKZF2 DEGRADERS | ONCOPIA THERAPEUTICS, INC. D/B/A PROTEOVANT THERAPEUTICS, INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-6369086-B1 | Substituted oxidole derivatives as protein tyrosine and as protein serine/threonine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2002-04-09 | — | — | US | disclosed |
| US-6350747-B1 | PROTEIN SERINE/THREONINE KINASE AND PROTEIN TYROSINE KINASE ENZYME INHIBITORS; ANGIOGENESIS INHIBITORS; ANTITUMOR AND ANTIPROLIFERATIVE AGENTS | GLAXO WELLCOME INC. | 2002-02-26 | — | — | US | disclosed |
| EP-1180105-A2 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2002-02-20 | — | — | EP | disclosed |
| EP-1165514-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-01-02 | — | — | EP | disclosed |
| WO-2000056710-A1 | 3-(ANILINOMETHYLENE) OXINDOLES AS PROTEIN TYROSINE KINASE AND PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-09-28 | — | — | WO | disclosed |
| WO-2000055159-A2 | SUBSTITUTED AZA-OXINDOLE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2000-09-21 | — | — | WO | disclosed |
| EP-0871628-A1 | QUINOLIZINONE TYPE COMPOUNDS | Abbott Laboratories (US) | 1998-10-21 | — | — | EP | disclosed |
| US-5726182-A | TREATMENT OF BACTERIAL INFECTIONS | ABBOTT LABORATORIES (US) | 1998-03-10 | — | — | US | disclosed |
| US-5599816-A | BACTERICIDE | ABBOTT LABORATORIES (US) | 1997-02-04 | — | — | US | disclosed |
| WO-1996039407-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109885-A1 | 2,3-DIHYDRO-1H-PYRROLO[3,2-B]PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | WEE1, WEE2, EGFR | MAPT 4266/4885MAPK1 169/4885RAB9A 4020/4885 |
| US-20240327402-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY | WEE1, WEE2, EGFR | MAPT 3517/4885MAPK1 211/4885RAB9A 3812/4885 |
| US-11834407-B2 | Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists | CHRM1, CHRM2, CHRM4 | MAPT 2822/4885MAPK1 1814/4885RAB9A 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.